ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
14.29
31.77
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
ACADIA Pharmaceuticals Inc
Gross Profit
ACADIA Pharmaceuticals Inc
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
|
Gross Profit
$851.3m
|
CAGR 3-Years
23%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
||
Abbvie Inc
NYSE:ABBV
|
Gross Profit
$37.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
||
Gilead Sciences Inc
NASDAQ:GILD
|
Gross Profit
$22B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
||
Amgen Inc
NASDAQ:AMGN
|
Gross Profit
$19.7B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
2%
|
||
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Gross Profit
$9.2B
|
CAGR 3-Years
13%
|
CAGR 5-Years
24%
|
CAGR 10-Years
29%
|
||
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Gross Profit
$12B
|
CAGR 3-Years
1%
|
CAGR 5-Years
15%
|
CAGR 10-Years
17%
|
ACADIA Pharmaceuticals Inc
Glance View
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 514 full-time employees. The company went IPO on 2004-05-27. The Company’s pipeline product candidates in CNS areas includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. The firm has initiated a Phase II study evaluating ACP-044 for the treatment of postoperative pain following bunionectomy surgery. The firm also initiated an additional Phase II study evaluating ACP-044 for the treatment of pain associated with osteoarthritis. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).
See Also
What is ACADIA Pharmaceuticals Inc's Gross Profit?
Gross Profit
851.3m
USD
Based on the financial report for Sep 30, 2024, ACADIA Pharmaceuticals Inc's Gross Profit amounts to 851.3m USD.
What is ACADIA Pharmaceuticals Inc's Gross Profit growth rate?
Gross Profit CAGR 5Y
25%
Over the last year, the Gross Profit growth was 41%. The average annual Gross Profit growth rates for ACADIA Pharmaceuticals Inc have been 23% over the past three years , 25% over the past five years .